News

Every patient in the study was VOC-free at the time of the data cut.

A whole genomic sequencing study shows what may be influencing risk of quadruple-agent regimen response in patients receiving daratumumab.

Research into ovarian follicular density in younger female sickle cell disease patients finds no effect from exposure to hydroxyurea.

Compared with infants kept on a standard dose of hydroxyurea, those receiving escalating doses showed greater increases in HbF and HB without significant toxicity.

A study in the Dominican Republic assessed the use of dose escalation of hydroxyurea for children in a single hospital with sickle cell anemia.

Research presented at ASH 2022 examined the ages of onset of ASSC in younger sickle cell disease patients treated with hydroxyurea.

The SPHRE trial in Tanzania show significant benefit for children at high stroke risk in sub-Saharan Africa.

Updated findings from the ongoing clinical trial investigating lovo-cel in sickle cell disease and persistent anemia allude to the possibility that a contributing factor of anemia was identified.

An in vitro assessment showed the promising molecule class should be advanced toward prospective clinical trials.

A total of 55 metabolites were significantly different between samples from patients with SCD at baseline and healthy control samples.

According to data presented at the ASH 2022 Annual Meeting, this is the first suggestion of a hydroxyurea-related impact on mito activity in patients with sickle cell disease.

Research indicates the long-term benefits of sustained use of two developed online interventions for younger patients diagnosed with eczema.

Recent research has identified two groups as high risk for developing asthma, with one noted as having early eczema and the other not having the skin condition.

In 2021, the USPSTF changed guidance on colorectal cancer screenings, reducing the recommended age of a colonoscopy from 50 to 45 years.

Eyes with bacillary detachment had higher fluid volumes, increased CST, EZ attenuation, and increased sub-RPE volume at baseline.

As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased. In recent years, GFAP has emerged as a valuable candidate to add to the existing panel.

Pauk Feuerstadt, MD, discusses some future applications of RBX2660.

After decades of unmet needs in the progressive form of vision loss, the complement inhibitor drug class is nearing the market for affected patients.

Close to half of patients with wet AMD treated with aflibercept could safely stop eye injection therapy after one year without further vision loss, according to the pilot study.

New research suggests lower central foveal thickness fluctuation scores with patients on ranibizumab were associated with the greatest gains in vision.

A look back at 2022, including new drug approvals, the significance of treatment for geographic atrophy, and what the future holds within the retina space. Veeral Sheth, MD joins to discuss in a Q&A.

Dr. Glasser shares perspective on the adoption of telehealth in ophthalmology and the importance of increased funding to provide sufficient reimbursement for all physician services.

Individuals living in lower-income situations were also more likely to have vision impairment, use eye care services less, and have lower adherence to eye examinations.

Macular holes in stage 2 progress faster than those in stages 3 and 4, making it beneficial to perform vitrectomy without delay in this population.

New research highlights the growing number of claims among all providers, including advanced practice practitioners and non-dermatologists, of Cal/BD foam usage for Medicare beneficiaries.

A discussion with Emily Strouphauer on her team's findings regarding mental health in pediatric psoriasis, as well as her views on helping younger patients facing these issues.

There was also higher neutralizing antibody titers against BA.4/5 with a lower hazard risk in the group with a breakthrough infection.

Adults with vision impairment had a lower prevalence of having health insurance coverage and a usual health care provider, and a higher prevalence of having an unmet health care due to cost.